Guardant Health, Inc. (GH) News
Track canonical SquawkNews coverage tagged to GH, Guardant Health, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 33 indexed stories across 18 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GH: Shield’s rapid scale-up, cost reductions, and broad coverage drive strong growth and market leadership
Q2 saw strong revenue and volume growth, with Shield now covering 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are expanding clinical use cases, while commercial win
EARNINGS | Sep 15, 2026, 01:13 PM UTC
L
GH: Shield now covers 80% of eligible patients, driving rapid commercial and clinical expansion
Q2 saw strong revenue and volume growth, with Shield expanding coverage to 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are driving clinical adoption, while Shield’s
EARNINGS | Sep 15, 2026, 12:38 PM UTC
L
Guardant Health Chief Information Officer Sold Shares Worth Over $632K
Kalia Kumud, an officer serving as Chief Information Officer, reported selling shares of Guardant Health. The sales were executed at a weighted average price of $158.0483 per share, with individual sale prices ranging fr
EQUITY | Sep 14, 2026, 10:21 PM UTC
L
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective
NEWS | Sep 14, 2026, 08:05 PM UTC
L
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Trea
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances
EQUITY | Sep 09, 2026, 07:46 PM UTC
L
UBS raises Guardant Health price target to $225 from $175
UBS maintained Guardant Health at Buy and raised its price target to $225.00 per share from $175.00.
EQUITY | Sep 09, 2026, 06:00 PM UTC
L
Guardant Health named to Business Insider’s 2027 innovation list
Guardant Health, Inc. said it was named to Business Insider’s “America’s Most Innovative Businesses 2027” list, receiving the highest available rating with five-star recognition limited to other 12 biotechnology research
EQUITY | Sep 08, 2026, 06:38 PM UTC
L
Guardant Health price target set at $203 by Rothschild & Co
Rothschild & Co announced a $203.00/share price target for Guardant Health, according to Benzinga ratings actions reported by TradingView News.
EQUITY | Sep 08, 2026, 12:26 PM UTC
L
BTIG maintains Guardant Health $195 price target
BTIG maintained its $195.00/share price target for Guardant Health, according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 09:53 AM UTC
M
Guardant Health’s Shield colorectal test covered in Carelon guidelines from Nov. 15
Guardant Health said its Shield™ blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines effective November 15.
EQUITY | Sep 01, 2026, 12:05 PM UTC
M
Guardant Health ordered to pay over $245.2M in patent ruling
A U.S. court has ordered Guardant Health to pay more than $245.2M to TwinStrand Biosciences and the University of Washington after finding patent infringement, TwinStrand said Monday.
REGULATION | Aug 24, 2026, 11:21 AM UTC
L
GH Reiterate Buy, $205 PT after results @ Canaccord
GH Reiterate Buy, $205 PT after results @ Canaccord
EARNINGS | Aug 03, 2026, 12:47 PM UTC
H
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 50 points on Friday. Shares of AXT Inc (NASDAQ: AXTI ) rose sharply after the company reported better-than-expected second-quarter financial results and is
EARNINGS | Jul 31, 2026, 02:05 PM UTC
L
Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidanc
Guardant Health shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates. Also, BTIG raised its price target on the stock from $190 to
EARNINGS | Jul 31, 2026, 12:58 PM UTC
H
GH Raises PT to $200
GH price target raised to $200
EQUITY | Jul 31, 2026, 12:42 PM UTC
L
GH +7.5% premarket after results
GH +7.5% premarket after results
EARNINGS | Jul 31, 2026, 11:51 AM UTC
L
ESRT, GH, INUV, KYN, NTRS file mixed shelf offerings
Companies file mixed shelf offerings
FX | Jul 31, 2026, 09:48 AM UTC
L
Guardant Health Sees 2026 Free Cash Flow Burn
Guardant Health forecasts 2026 cash burn
EARNINGS | Jul 30, 2026, 08:29 PM UTC
L
GH Q2 adj EPS ($0.42) vs est ($0.41), adj EBITDA ($55.9)Mm vs est ($50.28)Mm on revs $335Mm vs est $314.23Mm; guides FY revs $1.34-1.36B vs
GH Q2 adj EPS ($0.42) vs est ($0.41), adj EBITDA ($55.9)Mm vs est ($50.28)Mm on revs $335Mm vs est $314.23Mm; guides FY revs $1.34-1.36B vs est $1.314B; shares +5.2%
EQUITY | Jul 30, 2026, 08:12 PM UTC
L
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est
Guardant Health (NASDAQ: GH ) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.
EARNINGS | Jul 30, 2026, 08:07 PM UTC
H
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.5%, RIVN +/-7.9%, NXT +/-16.8%, MTZ +/-14.6%, AJG +/-7.2%, GH +/-14.1%, CTVA +/-
EARNINGS | Jul 30, 2026, 05:58 PM UTC
L
GH PT raised from $160 to $190, maintains Buy @ GUGG
GH PT raised from $160 to $190, maintains Buy @ GUGG
EQUITY | Jul 16, 2026, 12:57 PM UTC
L
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
EQUITY | Jul 15, 2026, 12:17 PM UTC
H
TMO MTD RVTY A GH Like names in Life Sciences into Q2 earnings for space @ Stifel
TMO MTD RVTY A GH Like names in Life Sciences into Q2 earnings for space @ Stifel
EARNINGS | Jul 14, 2026, 11:25 AM UTC
L
Guardant Health price target raised by $70 at Canaccord, here's why
Guardant Health price target raised by $70 at Canaccord, here's why
EQUITY | Jul 14, 2026, 10:54 AM UTC
H
Guardant Health price target raised to $175 from $130 at Morgan Stanley
Morgan Stanley raised the firm's price target on Guardant Health to $175 from $130 and keeps an Overweight rating on the shares. The firm is updating its model ahead of the earnings report.
EQUITY | Jul 09, 2026, 10:58 AM UTC
L
Bernstein Maintains Outperform on Guardant Health, Raises Price Target to $200
Bernstein analyst Eve Burstein maintains Guardant Health (NASDAQ: GH ) with a Outperform and raises the price target from $175 to $200.
EQUITY | Jul 02, 2026, 02:29 PM UTC
L
Guardant Health shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $160 to $190.
Guardant Health shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $160 to $190.
EQUITY | Jul 01, 2026, 06:02 PM UTC
L
BTIG Maintains Buy on Guardant Health, Raises Price Target to $190
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ: GH ) with a Buy and raises the price target from $160 to $190.
EQUITY | Jul 01, 2026, 04:48 PM UTC
M
GH: Bernstein Reinstates Outperform
Bernstein analyst Eve Burstein reinstates Guardant Health with an Outperform rating and $175 price target.
EQUITY | Jun 26, 2026, 01:03 PM UTC
M
GH: Barclays Raises PT
Barclays maintains overweight rating on Guardant Health and raises price target to $150
EQUITY | Jun 24, 2026, 02:55 PM UTC